Bluewater Bio will use the investment proceeds for current and future working capital needs.
Liberation Capital specialises in project finance for renewable energy and water/wastewater solutions and is led by Jeff Garwood, the former president and CEO of GE Water & Process Technologies. The private equity company focuses on small infrastructure projects with a preference for technologies and solutions that turn waste products into constituents of value.
The Bluewater Bio flagship technology is HYBACS, a nutrient removal solution for municipal and industrial wastewater treatment. Bluewater Bio has recently acquired FilterClear filters, a range of high-performance multimedia filters, and Water Innovate, the Cranfield University spin-out, including products such as N-Tox and MCR.
Daniel Ishag, CEO of Bluewater Bio, said his company was delighted to be concluding this transaction with Liberation Capital. "This transaction further validates Bluewater Bio’s achievements to date and Liberation Capital and its team is an ideal project financing platform partner for us going forward, enabling us to scale our business globally,” said Ishag.
Jeff Garwood, managing member of Liberation Capital, said: “We have tremendous respect for Bluewater Bio’s strategy, technology and team. Daniel and I share a similar vision and as such we’re proud to be part of funding their growth.”
